Sectors & IndustriesHealthcareBiotechnology

Best Biotech Stocks to Buy Now (2025)

Top biotech stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best biotech stocks to buy now. Learn More.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best biotechnology stocks to buy right now are:

Ptc Therapeutics (NASDAQ:PTCT) is the #1 top biotech stock out of 659 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Ptc Therapeutics (NASDAQ:PTCT) is: Value: A, Growth: B, Momentum: C, Sentiment: B, Safety: C, Financials: A, and AI: C.

Ptc Therapeutics (NASDAQ:PTCT) has a Due Diligence Score of 35, which is 11 points higher than the biotech industry average of 24.

PTCT passed 11 out of 33 due diligence checks and has average fundamentals. Ptc Therapeutics has seen its stock return 35.2% over the past year, overperforming other biotech stocks by 112 percentage points.

Ptc Therapeutics has an average 1 year price target of $61.85, an upside of 34.42% from Ptc Therapeutics's current stock price of $46.01.

Ptc Therapeutics stock has a consensus Buy recommendation according to Wall Street analysts. Of the 13 analysts covering Ptc Therapeutics, 46.15% have issued a Strong Buy rating, 15.38% have issued a Buy, 23.08% have issued a hold, while 0% have issued a Sell rating, and 15.38% have issued a Strong Sell.

Aurinia Pharmaceuticals (NASDAQ:AUPH) is the #2 top biotech stock out of 659 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Aurinia Pharmaceuticals (NASDAQ:AUPH) is: Value: B, Growth: B, Momentum: C, Sentiment: A, Safety: C, Financials: A, and AI: C.

Aurinia Pharmaceuticals (NASDAQ:AUPH) has a Due Diligence Score of 62, which is 38 points higher than the biotech industry average of 24.

AUPH passed 20 out of 33 due diligence checks and has strong fundamentals. Aurinia Pharmaceuticals has seen its stock return 41.94% over the past year, overperforming other biotech stocks by 119 percentage points.

Incyte (NASDAQ:INCY) is the #3 top biotech stock out of 659 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Incyte (NASDAQ:INCY) is: Value: A, Growth: A, Momentum: D, Sentiment: B, Safety: C, Financials: B, and AI: B.

Incyte (NASDAQ:INCY) has a Due Diligence Score of 47, which is 23 points higher than the biotech industry average of 24.

INCY passed 15 out of 33 due diligence checks and has strong fundamentals. Incyte has seen its stock return 11.34% over the past year, overperforming other biotech stocks by 89 percentage points.

Incyte has an average 1 year price target of $73.50, an upside of 16.1% from Incyte's current stock price of $63.31.

Incyte stock has a consensus Hold recommendation according to Wall Street analysts. Of the 10 analysts covering Incyte, 10% have issued a Strong Buy rating, 0% have issued a Buy, 90% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 6 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

Jade Biosciences (NASDAQ:JBIO) has an annual dividend yield of 32.68%, which is 27 percentage points higher than the biotech industry average of 6.07%.

Jade Biosciences's dividend payout ratio of 0% indicates that its high dividend yield might not be sustainable for the long-term.

Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 5.39%, which is -1 percentage points lower than the biotech industry average of 6.07%.

Dominari Holdings's dividend payout ratio of -7.1% indicates that its high dividend yield might not be sustainable for the long-term.

Novo Nordisk (Ozempic) (NYSE:NVO) has an annual dividend yield of 2.5%, which is -4 percentage points lower than the biotech industry average of 6.07%. Novo Nordisk (Ozempic)'s dividend payout is not stable, having dropped more than 10% ten times in the last 10 years. Novo Nordisk (Ozempic)'s dividend has shown consistent growth over the last 10 years.

Novo Nordisk (Ozempic)'s dividend payout ratio of 45.2% indicates that its dividend yield is sustainable for the long-term.

Biotech stocks were up 1.42% in the last day, and up 3.39% over the last week. Inozyme Pharma was the among the top gainers in the biotechnology industry, gaining 178.17% yesterday.

Inozyme shares are trading higher after the company announced BioMarin will acquire the company for about $270 million.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued biotech stocks right now are:

Puma Biotechnology (NASDAQ:PBYI) is the most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Puma Biotechnology has a valuation score of 43, which is 29 points higher than the biotech industry average of 14. It passed 3 out of 7 valuation due diligence checks.

Puma Biotechnology's stock has dropped -23.13% in the past year. It has overperformed other stocks in the biotech industry by 54 percentage points.

Harmony Biosciences Holdings (NASDAQ:HRMY) is the second most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 71, which is 57 points higher than the biotech industry average of 14. It passed 5 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has gained 19.65% in the past year. It has overperformed other stocks in the biotech industry by 97 percentage points.

Jazz Pharmaceuticals (NASDAQ:JAZZ) is the third most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Jazz Pharmaceuticals has a valuation score of 71, which is 57 points higher than the biotech industry average of 14. It passed 5 out of 7 valuation due diligence checks.

Jazz Pharmaceuticals's stock has dropped -1.37% in the past year. It has overperformed other stocks in the biotech industry by 76 percentage points.

55.64% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 109.82% over the next year.

2.65% of biotech stocks have a Zen Rating of A (Strong Buy), 3.97% of biotech stocks are rated B (Buy), 38.63% are rated C (Hold), 34% are rated D (Sell), and 20.75% are rated F (Strong Sell).